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Abstract
Locally produced growth hormone (GH) and IGF-I are key factors in the regulation of mam-
mary gland (MG) development and may be important in breast cancer development/pro-
gression. Somatostatin (SST) and cortistatin (CORT) regulate GH/IGF-I axis at various
levels, but their role in regulating GH/IGF-I in MGs remains unknown. Since obesity alters
the expression of these systems in different tissues and is associated to MG (patho) physi-
ology, we sought to investigate the role of SST/CORT in regulating GH/IGF-I system in the
MGs of lean and obese mice. Therefore, we analyzed GH/IGF-I as well as SST/CORT and
ghrelin systems expression in the mammary fat pads (MFPs) of SST- or CORT-knockout
(KO) mice and their respective littermate-controls fed a low-fat (LF) or a high-fat (HF) diet for
16wks. Our results demonstrate that the majority of the components of GH/IGF-I, SST/
CORT and ghrelin systems are locally expressed in mouse MFP. Expression of elements of
the GH/IGF-I axis was significantly increased in MFPs of HF-fed control mice while lack of
endogenous SST partially suppressed, and lack of CORT completely blunted, the up-regu-
lation observed in obese WT-controls. Since SST/CORT are known to exert an inhibitory
role on the GH/IGFI axis, the increase in SST/CORT-receptor sst2 expression in MFPs of
HF-fed CORT- and SST-KOs together with an elevation on circulating SST in CORT-KOs
could explain the differences observed. These results offer new information on the factors
(GH/IGF-I axis) involved in the endocrine/metabolic dysregulation of MFPs in obesity, and
suggest that CORT is not a mere SST sibling in regulating MG physiology.
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Introduction
The growth hormone (GH) / insulin-like growth factor I (IGF-I) axis plays a crucial role in
mammary gland development and breast cancer progression [1–3]. In fact, GH and its receptor
(GH-R) as well as IGF-I and its receptor (IGF-IR) have been found to be locally expressed in
both mammary gland epithelium and fat pads during all stages of gland development in every
mammalian species examined to date [4–7]. Locally produced GH is regulated during mamma-
ry gland development, reaching maximum levels in mammary epithelium during puberty (as-
sociated to the formation of terminal end buds) but is barely detectable in adult mice [4].
However, locally produced GH does not substitute for circulating GH in terms of promotion of
mammary gland development [8]. In this context, the main action of circulating/local GH on
the mammary fat pads (MFPs) seems to be stimulation of IGF-I production, as it has been
shown that IGF-I mediates all of the actions of GH in mammary gland morphogenesis
[2,9,10]. IGF-I, which is locally expressed in MFPs [11] and in mammary gland epithelium
[12,13], plays a direct role in ductal morphogenesis and mammary gland development. Indeed,
IGF-I knockout mice show impaired development of mammary gland structures [2] and epi-
thelial deletion of IGF-I results in a deficit in ductal branching [12,13]. In contrast to GH, local
production of IGF-I in stromal fraction could be more important than circulating IGF-I, at
least for ductal development [14]. Nevertheless, regulation of mammary gland physiology by
this system is likely more complex, as it interacts with other related peptides, such as prolactin
(PRL), and its receptor (PRL-R), which is a well-known key regulatory tandem of mammary
gland development and physiology [15].
GH and IGF-I have also been suggested to promote breast carcinogenesis based on several
epidemiologic studies indicating that circulating levels of GH and IGF-I are positively correlat-
ed with breast cancer risk [16–25] at least, among postmenopausal women [26]. In addition, in
vitro and in vivo studies of rodent and primate model systems show that GH and IGF-I can in-
duce mammary epithelial cell proliferation and differentiation while blocking apoptosis [10].
However, the precise role of the GH/IGF-I axis in breast cancer development and progression
is still not fully elucidated, especially in the context of obesity, a metabolic status that is tightly
coupled to breast cancer risk, at least, in postmenopausal women [27–29]. The fact that some
components of the GH/IGF-I axis are altered in xenographed mammary tumors from obese
mice [30] reinforce the crucial role that local GH/IGF-I axis plays in normal and pathologic
mammary gland development under different metabolic conditions.
Local expression of GH/IGF-I axis components is regulated in different tissues by circulat-
ing and locally produced inhibitory factors, as somatostatin (SST) and cortistatin (CORT), as
well as by stimulatory factors, like ghrelin [31–34]. However, the functional relevance and in-
teraction of these factors at the mammary gland level is still unknown. SST was originally dis-
covered by its ability to inhibit pituitary GH secretion [31], but, nowadays it is well established
that SST is a multifunctional, pleiotropic hormone that exerts multiple functions through a
family of five G-protein coupled receptors (GPCRs) with seven transmembrane domains
(TMDs), called sst1-5 [35]. On the other hand, CORT [36,37] is highly similar to SST in struc-
ture and sequence, which can explain their common functional abilities, including the inhibi-
tion of GH secretion [37,38], and their comparable binding profile to all ssts, which have been
shown to be expressed in normal and tumoral mammary gland [39]. Notwithstanding this,
CORT and SST show different tissue distribution patterns and exhibit several separate, even
opposite, actions [40], likely owing to the ability of CORT to bind additional receptors [i.e. the
ghrelin receptor or GH secretagogue receptor (GHS-R)] [41]. Ghrelin, which was identified in
stomach as the endogenous ligand of GHS-R [32], can be modified by the ghrelin-O-acyl trans-
ferase (GOAT) enzyme with an N-octanoic acid in the hydroxyl group of the third serine
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residue, an acylation that is critical to exert many of its functions and is essential for binding to
its receptor [42,43]. Interestingly, ghrelin is expressed in mammary gland [44], and induces
proliferation in vitro in breast cancer cell lines [45], however, GHS-R does not seem to be ex-
pressed in this tissue [46]. It should be noted that ghrelin gene also encodes different splicing
variants, as is the case of the mouse In2-ghrelin and human In1-ghrelin variants [47,48] recent-
ly identified by our group, being the expression levels of some of these variants higher than
those found for native ghrelin in human breast tumors [48].
In view of the crucial role of GH/IGF-I in mammary gland (patho)physiology, its necessary
interdependence with the SST/CORT/ghrelin systems, and the impact that diet-induced obesi-
ty (DIO) would likely have in the local expression of these regulatory systems, we hypothesize
that a local deregulation of GH/IGF-1 axis (and/or its regulatory systems) may occur in mam-
mary fat pads under obesity conditions and upon the lack of SST or CORT, which could there-
fore influence the (patho) physiology of the mammary gland. Therefore, the present study was
aimed at analyzing, for the first time, the expression pattern of these regulatory systems in the
MFPs of CORT and SST knockouts (KO;-/-) in parallel with their respective control mice
(+/+) fed a low-fat (LF; lean-control) or a high-fat (HF; obese-group) diets.
Materials and Methods
Animals
All experimental procedures were approved by the Animal Care and Use Committees of the
University of Cordoba. C57Bl/6J female mice were bred in-house and maintained under stan-
dard conditions of light (12-h light, 12-h dark cycle; lights on at 07:00 h) and temperature
(22–24°C), with free access to tap water/food.
A set of CORT-/-, SST-/- and their corresponding littermate controls (CORT+/+ and
SST+/+) mice generated from heterozygous breeding pairs (n = 12 mice/genotype) were
fed a LF diet (Research Diets, Gentofte, Denmark; D12450B; 10% Kcal fat, 70% Kcal carbo-
hydrates, 20% Kcal proteins) or HF diet (Research Diets; D12492; 60% Kcal fat, 20% Kcal
carbohydrates, 20% Kcal proteins] for 16 weeks, starting at 4 week of age, as previously re-
ported [49]. Mice body weights were monitored twice a week. At least one week prior to kill-
ing the mice, all of them were trained and handled in order to acclimate to personnel and
handling methods. All females under random cycling condition were killed by decapitation
without anesthesia. Trunk blood was collected and inguinal MFPs were harvested using
sharp scissors, starting from the proximal area close to the nipple towards the distal end of
the gland towards the spine of the animal, collecting all the adipose tissue delimiting the in-
guinal mammary area. MFPs constitute a heterogeneous population of cells that include adi-
pose stroma and epithelial cells, whose proportions may be modified under obesity
conditions. Samples were immediately frozen in liquid nitrogen and stored at -80°C until
their further processing.
Assessment of plasma leptin
Trunk blood was collected fromWT, CORT-KO and SST-KO mice after killing and immedi-
ately mixed with MiniProtease inhibitor (Roche; Barcelona, Spain), placed on ice, centrifuged
and plasma was stored at -80°C until leptin determination. Circulating leptin levels were as-
sessed by using a commercial ELISA kit (Millipore; Madrid, Spain).
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Total RNA isolation and retrotranscription
Total RNA from inguinal MFPs was isolated using TRIzol Reagent (Invitrogen, Barcelona,
Spain) following the manufacturer’s instructions and treated with DNase (Promega, Barcelona,
Spain). The amount of RNA recovered (before and after DNase treatment) was determined
using the NanoDrop2000 spectrophotometer (Thermo Scientific, Wilmington, EEUU). 1 μg of
RNA was reverse transcribed to cDNA using random hexamer primers [First Strand Synthesis
(MRI Fermentas, Hanover, MD)].
Quantitative real time PCR (qPCR)
qPCR reactions were performed using the Brilliant III SYBR Green QPCRMaster Mix (Strata-
gene, La Jolla, CA) in the Stratagene Mx3000p system. For each reaction, 10μl of master mix,
0.3μl of each primer, 8.4μl of distilled H2O and 1μl of cDNA (50 ng) in a 20μl total volume
were mixed. The qPCR was performed with a program consisting of the following steps: (1)
95°C for 3 min, (2) 40 cycles of denaturing (95°C for 20 sec) and annealing/extension (61°C for
20 sec) and (3) a last cycle where final PCR products were subjected to graded temperature-de-
pendent dissociation (55°C to 95°C where it increased 0.5°C/30 sec) to verify that only one
product was amplified. Total RNA samples that were not reversed transcribed and a no cDNA
control were run on each plate to control for genomic DNA contamination and to monitor po-
tential exogenous contamination, respectively. To control for variations in the amount of RNA
used in RT reaction and the efficiency of RT reaction, mRNA copy number of each transcript
of interest was adjusted by a normalization factor from two optimum housekeeping genes for
mammary fat pads: β-actin and GAPDH, using the Genorm 3.3 visual basic application, where
the expression of these housekeeping genes was not significantly altered (data not shown).
Specific primers (Table 1) for mouse transcripts were designed with Primer3 software and
validated using the same parameter reported previously [50,51]. Standard curves of each tran-
script were made and run in parallel with the experimental samples in order to quantify abso-
lute gene expression (copy number).
Statistical analysis
Samples from all groups within an experiment were processed at the same time. 2-way
ANOVA was used to compare the influence of the two factors [diet (LF, HF) and/or genotype
(WT, CORT-KO, SST-KO)] and their interaction, followed by Bonferroni post-hoc test. All
values are expressed as mean ± SEM; p<0.05 was considered significant. All statistical analyses
were performed using the GraphPad Prism 5.0 software (GraphPad Software Inc., La Jolla,
CA).
Results
Effect of HF diet on body weight
In order to confirm the obese status induced by the HF diet, body weights were recorded at the
end of the experiments and percentages of increase in HF-fed animals vs. LF-fed mice are de-
picted in Fig 1. In CORT group, HF-feeding dramatically augmented the percentage of weight
in female WT and CORT-KO mice gain after 16 weeks of diet compared to LF-fed controls.
Similarly, in SST group, HF-feeding caused a strong increase in both WT and SST-KOmice
body weights compared to LF-fed controls.
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Effect of HF diet on circulating leptin levels
In order to further support the obese status induced by the HF diet, plasma leptin levels were
analyzed in SST and CORT groups under LF- and HF- feeding (Fig 2). Importantly, we ob-
served that HF diet caused a significant increase of plasma leptin levels of obese mice compared
to lean mice (p = 0.002 in CORT group and p = 0.003 in SST group).
GH/IGF-I, SST/CORT and ghrelin systems are expressed in mouse
mammary fat pads under normal feeding conditions
qPCR analysis demonstrated that the components of GH/IGF-I and PRL systems are expressed
in MFPs of female mice under normal feeding conditions. GH-R, IGF-I, IGF-II, IGF-IR and
PRL-R were expressed at high levels, whereas GH and PRL expression was not detectable (Fig
3, top-panel). The majority of sst subtypes were expressed in mouse MFPs, being their relative
abundance sst2>sst4>sst5TMD1>sst1 = sst3 (Fig 3, middle-panel). Conversely, full-length,
native sst5 and the ligands (SST and CORT) were not expressed substantially in MFPs. Ghrelin
Table 1. Specific set of primers for amplification of mouse transcripts used for quantitative real-time RT-PCR.
Template GenBank
Accession
Primer sequence Nucleotide
Position
Product size
(bp)
GH NM_008117 Sn: CCTCAGCAGGATTTTCACCA As: CTTGAGGATCTGCCCAACAC Sn 412 As 553 142
GH-R BC075720 Sn: GATTTTACCCCCAGTCCCAGTTC As:
GACCCTTCAGTCTTCTCATCCACA
Sn1155 As 1352 198
IGF-I NM_010512.3 Sn: TCGTCTTCACACCTCTTCTACCT As:
ACTCATCCACAATGCCTGTCT
Sn31 As 232 202
IGF-II NM_010514 Sn: GCTTGTTGACACGCTTCAGTT As:
GAAGTACGGCCTGAGAGGTAGA
Sn 555 As 751 197
IGF-IR NM_010513 Sn: TGGAGTGCTGTATGCTTCTGTG As: CTGGTTTCGGGTTCATCCTT Sn 3512 As 3691 180
PRL NM_011164.2 Sn: GGCCATCTTGGAGAAGTGTG As: ACAGATTGGCAGAGGCTGAA Sn 20 As 156 137
PRL-R NM_011169.5 Sn: TGGGAGATCCACTTCACAGG As: GGCCACAATGATCCACACA Sn 1271 As 1459 189
SST NM_009215.1 Sn: TCTGCATCGTCCTGGCTTT As: CTTGGCCAGTTCCTGTTTCC Sn 138 As 250 113
CORT NM_007745.3 Sn: AAGAGACCCTCGTCCACCAA As:
ACCAGGCAAGGAAAGTCAGAAG
Sn52 As 264 213
sst1 NM_009216 Sn: TGCCCTTTCTGGTCACTTCC As: AGCGGTCCACACTAAGCACA Sn 757 As 891 135
sst2 NM_001042606 Sn: CCCATCCTGTACGCCTTCTT As: GTCTCATTCAGCCGGGATTT Sn 925 As 1058 134
sst3 NM_009218.3 Sn: GCCTTCTTCGGCCTCTACTT As: GAATGCGACGTGATGGTCTT Sn 1292 As 1430 139
sst4 NM_009219.3 Sn: AGGCTCGTGCTAATGGTGGT As: GGATGAGGGACACATGGTTG Sn 860 As 980 121
sst5 NM_011425.2 Sn: ACCCCCTGCTCTATGGCTTT As: GCTCTATGGCATCTGCATCCT Sn1215 As 1319 105
sst5TMD4 GQ359775 Sn: GTCCACCCTCTCCGCTCA As: GCAGGTTCGCAGAGGACATC Sn 415 As 545 131
sst5TMD2 GQ359776 Sn: CAGTTCACCCGTACTGTGGCAT As:
CACAGCTTCAGGGTGGGTAA
Sn358 As 489 132
sst5TMD1 GQ359777 Sn: AACGTGTATATCCAGACAAGAGTGG As:
TCCCAGAAGACAACACCACA
Sn 217 As 368 152
Ghrelin NM_021488.4 Sn: TCCAAGAAGCCACCAGCTAA As: AACATCGAAGGGAGCATTGA Sn163 As 288 126
In2-Ghrelin DO_993169 Sn: GCTGTCTTCAGGCACCATCT As: GTGGCTTCTTGGATTCCTTTC Sn 1221 As 1444 224
GOAT NM_001126 Sn: ATTTGTGAAGGGAAGGTGGAG As:
CAGGAGAGCAGGGAAAAAGAG
Sn 473 As 592 120
GHS-R NM_177330.3 Sn: TCAGGGACCAGAACCACAAA As: CCAGCAGAGGATGAAAGCAA Sn 1002 As 1072 71
β-actin NM_007393.2 Sn: CTGGGACGACATGGAGAAGA As: ACCAGAGGCATACAGGGACA Sn 313 As 517 205
GAPDH XM_001473623.1 Sn: ATGGCCTTCCGTGTTCCTAC As: GCCTGCTTCACCACCTTCTT Sn 757 As 860 104
Bp base pairs; Sn sense; As antisense.
doi:10.1371/journal.pone.0120955.t001
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system is also expressed in mouse MFPs, where the In2-ghrelin variant was found to be more
expressed than native ghrelin, while GOAT enzyme and ghrelin receptor (GHS-R) were ex-
pressed at negligible levels (Fig 3, bottom-panel).
Impact of DIO and loss of SST/CORT on GH/IGF-I axis in mouse
mammary fat pads.
To analyze the effect of diet-induced obesity and the implication of SST and CORT in the regu-
lation of GH/IGF-I, SST/CORT and ghrelin systems expression in the MFPs, we used CORT-
and SST-KO female mice and their respective control fed a LF or HF diet (Fig 4).
DIO drastically influenced the expression of GH/IGF-I system in the MFPs of control mice.
Specifically, expression of GH-R, IGF-I and IGF-IR, was significantly elevated in both control
groups (CORT+/+ and SST+/+). As observed before, GH and PRL expression was again unde-
tectable and no significant changes were observed in IGF-II and PRL-R levels in mammary fat
pads of WT groups.
Interestingly, loss of CORT (Fig 4, left-panels) or SST (Fig 4, right-panels) did not signifi-
cantly influence GH/IGF-I system expression under LF-diet, but clearly impacted the obesity-
associated changes. Specifically, CORT-KO mice fed a HF-diet did not show the elevation in
GH-R, IGF-I and IGF-IR expression observed in control mice (Fig 4, left-panels). In contrast,
Fig 1. Impact of LF- and HF- diet on body weight in WT, CORT-KO and SST-KO female mice. Values represent percentage of body weight increase
compared to 100% of LF diet fed mice. Global differences by 2-way ANOVA are shown at the top of each graphic (G: genotype effect; D: diet effect I: effect of
interaction between genotype and diet; *, p<0.05; **, p<0.01; ***, p<0.001). Asterisks above the bars (*, p<0.05; ***, p<0.001) indicate significant
differences between groups by Bonferroni post-hoc.
doi:10.1371/journal.pone.0120955.g001
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loss of SST under obese conditions did not prevent the raise in IGF-IR but significantly blunted
the increase in GH-R and IGF-I expression observed in HF-diet control mice (Fig 4; right-pan-
els). In addition, MFPs of HF-fed CORT-KO showed significantly lower levels of PRL-R ex-
pression than those of their HF-diet WT counterparts, an observation which was not fully
parallel in SST-null mice. Nevertheless, it should be noted that MFPs in both CORT-KO and
SST-KO animals exhibited an overall decrease in PRL-R expression due to their genotype
(2-way ANOVA analysis, p = 0.0051 and p = 0.0261, in CORT-KO and SST-KO mice,
respectively).
Impact of DIO and loss of SST/CORT on SST/CORT axis in mouse
mammary fat pads
Similar to that found in GH/IGF-I axis, loss of CORT and SST did not significantly alter the ex-
pression of the majority of ssts in the MFPs of mice fed with a LF-diet, although we observed
that mean of sst2 expression levels in SST-KO LF is 42% with respect to its WT-LF counterpart
mice (p = 0.243) (Fig 5). There was an overall effect of the diet in the expression of sst1, sst2
and sst4 as assessed by 2-way ANOVA. A more detailed analysis of this effect revealed an ap-
parent increase of the expression of sst1 and sst4 in HF-fed CORT+/+ mice, while sst1 and sst4
means in HF-fed SST +/+ were 123% (p = 0.995) and 189% (p = 0.995) of the LF-fed, respec-
tively. Likewise, a marked, significant increase was observed for sst1 and sst4 expression in HF-
fed SST-KO (Fig 5, right-panel) but not in HF-fed CORT-KO mice (Fig 5, left-panel).
Fig 2. Plasma leptin levels in WT, CORT-KO and SST-KOmice fed under LF and HF diets. Values represent mean ± SEM of ng/ml of plasma leptin.
Global differences by 2-way ANOVA are shown at the top of each graphic (G: genotype effect; D: diet effect I: effect of interaction between genotype and diet;
*, p<0.05; **, p<0.01; ***, p<0.001). Asterisks above the bars (*, p<0.05) indicate significant differences between groups by Bonferroni post-hoc.
doi:10.1371/journal.pone.0120955.g002
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Fig 3. Characterization of GH/IGF-I axis and the regulatory SST/CORT/ghrelin/receptors system in
mammary fat pads of female mice (expressed as absolute copy number/50 ng total cDNA). Values
represent means ± SEM of the mRNA copy number of each transcript (n = 5–6 mice).
doi:10.1371/journal.pone.0120955.g003
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Importantly, sst2, which was not significantly elevated by HF-diet in control (+/+) mice, was
up-regulated by the lack of CORT and SST. The expression of sst3 was not significantly altered
by the diet or the genotype in any group.
Impact of DIO and loss of SST/CORT on ghrelin axis in mouse
mammary fat pads
DIO did not seem to cause major, significant changes in the expression of ghrelin system com-
ponents (ghrelin, In2-ghrelin and GOAT) in any of the groups analyzed (Fig 6; GHS-R expres-
sion was under the detection limit).
Discussion
This study confirms and extends previous data in human and mice [4–7,52], by showing that
some of the components of GH/IGF-I axis are expressed in the mammary fat pads of mature
virgin C57Bl/6 female mice. Specifically, IGF-I, IGF-IR, GH-R and PRL-R (which shares a
common ancestor with GH-R due to gene duplication) [53] are expressed at high levels in
mouse MFPs, while GH (and PRL) expression is barely detectable, at least in mature female
mice. These data are consistent with previous studies [4] and reinforce the idea that circulating,
rather than locally produced GH acts on MFPs through GH-R to stimulate IGF-I production,
which, in turn, can be acting in an autocrine or paracrine fashion to regulate mammary gland
development [3,10–14,54,55]. In fact, locally produced IGF-I has been shown to be necessary
for mammary gland development [3,10–14] and could be involved in the progression of mam-
mary gland malignancies [10]. In this context, obesity, as a metabolic situation with elevated
plasma IGF-I [56], has been associated with a higher risk of developing breast cancer [57,58].
Moreover, since obesity have been shown to markedly alter the expression pattern of GH/
IGF-I axis (as well as SST/CORT and ghrelin systems) in other tissues [56,59], we hypothesized
that a similar deregulation may also occur in mammary gland, which could therefore influence
the (patho)physiology of the mammary gland. Therefore, in order to understand the local
changes in the GH/IGF-I axis in response to obesity, in the present study, the expression of the
different components of the GH/IGF-I axis was evaluated in the MFPs of diet-induced obese
female mice. To the best of our knowledge, this is the first comprehensive characterization of
this system in the MFPs of obese females. Importantly, our data show a clear elevation of
IGF-I, its receptor and GH-R in the MFPs of diet-induced obese female mice. These results are
consistent with previous data showing up-regulation of IGF-IR in the mammary gland of
obese women [60] and suggest a mechanism (up-regulation of local expression of the compo-
nents of the GH/IGF-I axis) which could explain the higher risk of developing mammary ma-
lignancies observed in obese individuals [28]. It has to be noted that LFD and HFD are
micronutrient-matched diets, and therefore, the changes in transcript expression patterns ob-
served herein should be due to intrinsic DIO-associated alterations (increased dietary fat con-
tent and/or fat storage) rather than to the presence/effect of specific diet components. In line
with this, and taking into account that obesity is associated to suppressed GH release [56], it
Fig 4. Impact of diet-induced obesity on the expression of GH-IGF-I axis in the mammary fat pads of
CORT-KO, SST-KO and their respective control mice.mRNA levels of GH-R, IGF-I, IGF-II, IGF-IR and
PRL-R were measured by qPCR. Values represent means ± SEM of the mRNA copy number of each
transcript adjusted by the normalization factor (n = 5–6). Global differences by 2-way ANOVA are shown at
the top of each graphic (G: genotype effect; D: diet effect I: effect of interaction between genotype and diet; *,
p<0.05; **, p<0.01; ***, p<0.001). Asterisks above the bars (*, p<0.05; **, p<0.01; ***, p<0.001) indicate
significant differences between groups by Bonferroni post-hoc.
doi:10.1371/journal.pone.0120955.g004
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seems reasonable to propose that other factors (leptin, insulin, adipokines, inflammatory fac-
tors, etc.) should contribute to the increased gene expression of GH/IGF-1 axis components.
SST/CORT and ghrelin systems, which finely regulate GH/IGF-I axis in different tissues
[32–35] and may be also involved in mammary gland (patho)physiology [25,29], were also
found to be expressed in MFPs. Interestingly, expression of both SST and CORT in mouse
MFPs was under the detection limits, which is consistent with previous studies [61] and sug-
gests a marginal or inexistent role for the local production of these ligands in mammary gland
physiology. In contrast, the majority of ssts are expressed at detectable levels in the MFPs,
where sst2 and sst4 are present at highest levels. Similar expression patterns with sst2 predomi-
nance have been observed in human normal and neoplastic [62,63] mammary tissues, confirm-
ing the potential role of SST and CORT in regulating MFP physiology. On the other hand,
ghrelin and the spliced In2-ghrelin variant were substantially expressed in MFPs, which is con-
sistent with previous reports showing expression of ghrelin [44,45] and In1-ghrelin variant
(the human counterpart of mouse In2-ghrelin) [48] in human mammary glands. However,
GOAT, the enzyme responsible for ghrelin acylation (described in human mammary gland
[64], and GHS-R (not found in mammary tissue [46]) were expressed at very low levels or even
under the detection limit.
It has been previously shown that the expression of SST/CORT and ghrelin axes is modulat-
ed under metabolic conditions (i.e. obesity) in several tissues [56]. Similarly, in this study we
observed an effect of the diet in the expression of sst1, sst2 and sst4, which appeared to be upre-
gulated, perhaps as a compensatory, inhibitory, mechanism in response to GH/IGF-I axis upre-
gulation. Inasmuch as local expression of GH/IGF-I axis is finely regulated by SST and CORT
in several tissues [40], we analyzed expression of IGF-I, IGF-IR and GH-R in SST and CORT
KOmice under LF- and HF-diets. Surprisingly, lack of SST or CORT did not influence expres-
sion of GH/IGF-I components under LFD conditions, despite the fact that circulating GH is el-
evated in both mouse models and that SST-KO but not CORT-KO mice have increased levels
of serum IGF-I, as we have previously reported [50,65]. However, it is noteworthy that lack of
SST partially suppressed while lack of CORT completely blunted the up-regulation observed in
obese (HF-fed) controls compared to lean (LF-fed) control mice. Our study also provides the
first data on the regulation of PRL system components in mammary tissue of CORT-KO and
SST-KO mice. Specifically, we observed that PRL-R expression is down-regulated in the ab-
sence of CORT and SST, suggesting that, at mammary gland level, CORT and SST can exert a
regulatory role on PRL signaling. The significant increase in expression levels of sst2 (the main
sst-receptor involved in the inhibitory actions of SST/CORT at many tissues) in MFPs of HF-
fed CORT-KO and SST-KOmice could, in part, help to explain the blockade in the obesity-in-
duced up-regulation of GH/IGF-I system observed in these two models as compared with their
respective controls (WT-mice). In addition, a compensatory increase in SST levels (circulating
and stomach mRNA) observed in CORT-KO mice [50] could provide an explanation to why
the obesity-induced up-regulation of GH/IGF-I system is completely blunted only in
CORT-KO, since it has been previously reported that SST can directly decrease the expression
of GH-R, IGF-I and IGFI-R in a variety of tissues [66–68]. In the current study, constraints in
Fig 5. Impact of diet-induced obesity on the expression of SST/CORT/receptor subtypes in the
mammary fat pads of CORT-KO, SST-KO and their respective control mice.mRNA levels of sst1, sst2,
sst3, sst4 were measured by qPCR. Values represent means ± SEM of the mRNA copy number of each
transcript adjusted by the normalization factor (n = 5–6). Global differences by 2-way ANOVA are shown at
the top of each graphic (G: genotype effect; D: diet effect I: effect of interaction between genotype and diet; *,
p<0.05; **, p<0.01; ***, p<0.001). Asterisks above the bars (*, p<0.05; **, p<0.01) indicate significant
differences between groups by Bonferroni post-hoc.
doi:10.1371/journal.pone.0120955.g005
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sample availability did not allow us to determine whether changes in mRNA levels observed in
the MFPs of these mice models are proportionately translated into functional protein levels,
which represents a limitation for our work. This caveat notwithstanding, our findings, when
viewed together, clearly support a dissimilar effect of the lack of endogenous SST or CORT in
the expression of GH/IGF-I axis components in the mouse MFPs.
In conclusion, our results provide new, original information on key growth factors (GH/
IGF-I axis) likely involved in the dysregulation of endocrine/metabolic homeostasis of MFPs in
obesity, and indicate that endogenous CORT and SST may be directly involved in the obesity-
induced changes observed in GH/IGF-I system in MFPs. In addition, our data also suggest that
endogenous CORT is not a simple SST analogue in regulating mammary gland physiology. Al-
together, our findings can offer new cues to identify novel molecular targets for diagnosis and/
or future treatment of mammary pathologies including breast cancer. Further studies focused
on the use of GH-R/IGF-1R antagonists in mouse models developing MG tumors could help to
elucidate the possible therapeutic role of these factors in MG pathophysiology.
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